Cargando…
A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1)
Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-modified...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518243/ https://www.ncbi.nlm.nih.gov/pubmed/34654435 http://dx.doi.org/10.1186/s12951-021-01063-4 |
_version_ | 1784584181527871488 |
---|---|
author | Zhang, Zhanxia Zhang, Junqian Tian, Jianhui Li, Hegen |
author_facet | Zhang, Zhanxia Zhang, Junqian Tian, Jianhui Li, Hegen |
author_sort | Zhang, Zhanxia |
collection | PubMed |
description | Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-modified polydopamine (PDA) nanomedicine used in photothermal therapy was designed for siRNA delivery. The designed nanovector can undergo photothermal conversion with good biocompatibility. Importantly, this genetic nanomedicine was selectively delivered to liver cancer cells by FA through receptor-mediated endocytosis. Subsequently, the siRNA cargo was released from the PDA nanomedicine into the tumor microenvironment by controlled release triggered by pH. More importantly, the genetic nanomedicine not only inhibited liver cancer cell proliferation but also promoted liver cell apoptosis by slowing ROC1 activity, suppressing the Neddylation pathway, enabling the accumulation of apototic factor ATF4 and DNA damage factor P-H2AX. Combined with photothermal therapy, this genetic nanomedicine showed superior inhibition of the growth of liver cancer in vitro and in vivo. Taken together, the results indicate that this biodegradable nanomedicine exhibits good target recognition, an effective pH response, application potential for genetic therapy, photothermal imaging and treatment of liver cancer. Therefore, this work contributes to the design of a multifunctional nanoplatform that combines genetic therapy and photothermal therapy for the treatment of liver cancer. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01063-4. |
format | Online Article Text |
id | pubmed-8518243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85182432021-10-20 A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) Zhang, Zhanxia Zhang, Junqian Tian, Jianhui Li, Hegen J Nanobiotechnology Research Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-modified polydopamine (PDA) nanomedicine used in photothermal therapy was designed for siRNA delivery. The designed nanovector can undergo photothermal conversion with good biocompatibility. Importantly, this genetic nanomedicine was selectively delivered to liver cancer cells by FA through receptor-mediated endocytosis. Subsequently, the siRNA cargo was released from the PDA nanomedicine into the tumor microenvironment by controlled release triggered by pH. More importantly, the genetic nanomedicine not only inhibited liver cancer cell proliferation but also promoted liver cell apoptosis by slowing ROC1 activity, suppressing the Neddylation pathway, enabling the accumulation of apototic factor ATF4 and DNA damage factor P-H2AX. Combined with photothermal therapy, this genetic nanomedicine showed superior inhibition of the growth of liver cancer in vitro and in vivo. Taken together, the results indicate that this biodegradable nanomedicine exhibits good target recognition, an effective pH response, application potential for genetic therapy, photothermal imaging and treatment of liver cancer. Therefore, this work contributes to the design of a multifunctional nanoplatform that combines genetic therapy and photothermal therapy for the treatment of liver cancer. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01063-4. BioMed Central 2021-10-15 /pmc/articles/PMC8518243/ /pubmed/34654435 http://dx.doi.org/10.1186/s12951-021-01063-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Zhanxia Zhang, Junqian Tian, Jianhui Li, Hegen A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_full | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_fullStr | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_full_unstemmed | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_short | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_sort | polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target nedd8-e3 ligase roc1 (rbx1) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518243/ https://www.ncbi.nlm.nih.gov/pubmed/34654435 http://dx.doi.org/10.1186/s12951-021-01063-4 |
work_keys_str_mv | AT zhangzhanxia apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT zhangjunqian apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT tianjianhui apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT lihegen apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT zhangzhanxia polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT zhangjunqian polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT tianjianhui polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT lihegen polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 |